TY  - JOUR
AU  - Ferdinandus, Justin
AU  - Kaul, Helen
AU  - Fosså, Alexander
AU  - Hüttmann, Andreas
AU  - Keil, Felix
AU  - Ko, Yon-Dschun
AU  - Hitz, Felicitas
AU  - Schwarz, Michaela
AU  - Trenker, Corinna
AU  - Kerkhoff, Andrea
AU  - Staib, Peter
AU  - Wille, Kai
AU  - Dresel, Irmgard
AU  - Hahn, Dennis
AU  - Hertenstein, Bernd
AU  - Moosmann, Peter
AU  - Mey, Ulrich
AU  - Balabanov, Stefan
AU  - Armytage, Tasman
AU  - Roncolato, Fernando
AU  - Hellmuth, Johannes C
AU  - Hertzberg, Mark
AU  - Kobe, Carsten
AU  - Klapper, Wolfram
AU  - Baues, Christian
AU  - Eich, Hans-Theodor
AU  - Kreissl, Stefanie
AU  - Fuchs, Michael
AU  - Jablonski, Janina
AU  - Schneider, Gundolf
AU  - Tharmaseelan, Hishan
AU  - Eichenauer, Dennis A
AU  - von Tresckow, Bastian
AU  - Borchmann, Peter
AU  - Bröckelmann, Paul J
TI  - Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
JO  - Journal of clinical oncology
VL  - nn
SN  - 0732-183X
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2025-01445
SP  - nn
PY  - 2025
N1  - epub
AB  - Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS-cHL). We report feasibility and efficacy of PET-guided BrECADD as first-line treatment in older patients with AS-cHL.Patients with AS-cHL aged 61-75 years were enrolled in a phase II single-arm cohort of the HD21 trial (ClinicalTrials.gov identifier: NCT02661503). Patients with negative PET/computed tomography after 2×BrECADD (PET2) received a total of 4×BrECADD, while PET2-positive patients received 6×BrECADD. The primary end point was the centrally reviewed complete remission (CR) rate after the end of chemotherapy (EOC). Secondary end points included feasibility, adverse events, treatment-related morbidity (TRMB), progression-free survival (PFS), overall survival (OS), and health-related quality of life (HRQoL).Between June 2020 and April 2023, 85 patients were enrolled, of whom 83 with a median age of 67 years (range, 61-75) were analyzed in the intention-to-treat cohort. Most prevalent ≥grade 3 toxicities included leukopenia (n = 80 [96
LB  - PUB:(DE-HGF)16
C6  - pmid:40674676
DO  - DOI:10.1200/JCO-25-00439
UR  - https://inrepo02.dkfz.de/record/302998
ER  -